Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Bailliere'S Clinical Haematology|December 1, 1994
Oral iron-chelating therapy: the L1 experienceF N al-Refaie, A V HoffbrandEuropean Journal of Haematology|November 1, 1994
Deferiprone-associated myelotoxicityF N al-Refaie, B Wonke, A V HoffbrandJournal of Clinical Pathology|February 1, 1995
Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overloadF N al-Refaie, C E De Silva, B Wonke, et al.British Journal of Haematology|February 1, 1995
Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overloadF N al-Refaie, L N Sheppard, P Nortey, et al.Acta Haematologica|January 1, 1993
Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-oneF N al-Refaie, P A Veys, S Wilkes, et al.British Journal of Haematology|October 1, 1992
Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1F N al-Refaie, D G Wickens, B Wonke, et al.European Journal of Haematology|March 1, 1994
Differential toxicity of alpha-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitroJ M Cunningham, F N al-Refaie, A E Hunter, et al.Journal of Clinical Pathology|July 1, 1994
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamineF N al-Refaie, B Wonke, D G Wickens, et al.Blood|August 1, 1992
Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia majorF N al-Refaie, B Wonke, A V Hoffbrand, et al.British Journal of Haematology|September 1, 1995
Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron ChelatorsF N al-Refaie, C Hershko, A V Hoffbrand, et al.Pageof 2